

Who can administer

May be administered by registered competent doctor or nurse/midwife

Important information

- Should not be initiated in patients with active infections until infections are controlled
- Before the administration of each dose, the patient should be examined for the presence of infection, and consideration given to delaying treatment should infection be present
- In order to improve the traceability of biological medicinal products, **the name and the batch number of the administered product should be clearly recorded.**
- Monitoring requirements - see below
- Note: This drug is also available as a subcutaneous injection- doses are not interchangeable for the different formulations

Available preparations

ORENCIA 250 mg powder for concentrate for solution for infusion

Reconstitution

Water for Injection

10ml per 250mg vial

- **MUST USE** the silicone-free disposable syringe provided with each vial and an 18-21 gauge needle.
- Rotate with gentle swirling until the contents are completely dissolved
- DO NOT SHAKE
- Vent the vial with a needle to dissipate any foam that may be present
- Only use the solution if it is clear and colourless to pale yellow

Infusion fluids

Sodium chloride 0.9%

Methods of intravenous administration

Intermittent Intravenous Infusion

- From a 100ml bag of Sodium Chloride 0.9%, withdraw a volume equal to the volume of the dose (for 2 vials remove 20ml, for 3 vials remove 30ml, for 4 vials remove 40ml).
- Maximum permitted concentration is 10mg per ml
- Slowly add the reconstituted abatacept from each vial into the infusion bag using the same silicone-free disposable syringe provided with each vial, and gently mix
- Administer using an infusion set with a sterile, non-pyrogenic, low protein binding filter (pore size 0.2µm to 1.2µm). e.g. Baxter RMC 9614 line with an extension set plus a Braun Sterifix 0.2micrometer infusion filter ref. no. 4099303.
- Administer required dose over 30 minutes

Dose in adults

Indication: Rheumatoid arthritis, Psoriatic arthritis

Dosing information		
Body weight	Dose	Number of vials
Less than 60kg	500mg	2
60 to 100kg	750mg	3
Greater than 100kg	1000mg	4

- The dose should be repeated two and four weeks after the first infusion, then every 4 weeks thereafter

Monitoring

- Please also consult Medication Protocol: Management of Infusion Related Patient Reactions in nurse-led infusion settings in GUH. QPulse
- Monitor patient for infusion related reactions for one hour from the start of the infusion ^(ref 1)

Further information

- Can interfere with some readings of blood glucose monitor ^(ref 2)

Storage

- Store vials at 2-8°C in the original packaging to protect from light

References

SPC Orenzia 01 February 2022

1: Abatacept Prescription sheet - Rheumatology day ward Updated February 2014

2: Injectable medicines information guide Medusa September 26 2022

Therapeutic classification

Immunosuppressant